Compare Becton Dickinson and Co (BDX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Becton Dickinson and Co trades at $155.18 (market cap $41.51B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.41. The key difference: Becton Dickinson and Co pays a 2.79% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Becton Dickinson and Co is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| BDX | YINN | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.39 | $56.62 |
52-Week Low | $135.49 | $21.45 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
YINN, the Direxion Daily FTSE China Bull 3x ETF, trades at $25.25, down 0.43% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral and RSI_6 suggests overbought conditions. Recent sentiment has improved with a Seeking Alpha rating upgrade from bearish to neutral, citing China's relative undervaluation and improved macro backdrop, though concerns remain about the fund's leveraged structure and value trap risks in Chinese equities.
The outlook for YINN is cautiously optimistic, driven by China's tech sector momentum and substantial government AI investment plans. However, significant risks include geopolitical tensions with the U.S., the fund's 3x leverage amplifying volatility, and ongoing regulatory uncertainties. Investors should weigh China's economic stimulus against structural challenges in the market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
